Literature DB >> 24367863

The use of serum hCG as a marker of tumor progression and of the response of metastatic urothelial cancer to systemic chemotherapy.

Karen Malkhasyan1, Hari A Deshpande2, Adebowale J Adeniran3, John W Colberg4, Daniel P Petrylak2.   

Abstract

This case confirms the observation that urothelial carcinomas can secrete beta-hCG, and that beta-hCG can potentially be used as a marker of a patient's clinical response to treatment. Prospective studies are clearly warranted by these observations.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24367863

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  2 in total

1.  Urothelial carcinoma of the prostate with raised β-hCG levels: a case report.

Authors:  Julia Sołek; Marta Kalwas; Magdalena Sobczak; Sylwia Dębska-Szmich; Piotr Kupnicki; Dorota Jesionek-Kupnicka
Journal:  J Med Case Rep       Date:  2022-06-15

2.  CGB5 expression is independently associated with poor overall survival and recurrence-free survival in patients with advanced gastric cancer.

Authors:  Yuxin Yang; Yonghong Shi; Yanjuan Hou; Ying Lu; Jinliang Yang
Journal:  Cancer Med       Date:  2018-02-23       Impact factor: 4.452
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.